TY - JOUR T1 - 外部射频作为一种新型的体外治疗肺气肿JF - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.01422-2020 SP - 2001422 AU - 和田，武行AU - 颚，仁ERH AU - 鹤田，正史AU - 森谷，松下幸之助AU - 筒井，麦AU - 潭，安东尼AU - Vasilescu，DRAGOS M. AU - 祥，松仁AU - 山崎，箕AU - 利希滕斯坦，萨穆埃尔AU - 汉荣，林赛AU - 吉尔巴特，丹AU- 男人，保罗AU - 仙，唐D. Y1 - 2020年1月1日UR - //www.qdcxjkg.com/content/early/2020/05/19/13993003.01422-2020.abstract N2 - 慢性阻塞性肺病是其特征在于，肺组织，导致肺泡组织破坏，肺泡空间，气体交换差，气道塌陷的放大破坏由于弹性反冲[1]的损失。肺减容手术（LVRS）可有效降低长期发病率和重度肺气肿患者谁拥有上叶病的优势，并且能够忍受手术过程[2，3]死亡率。然而，金融成本和过程的围手术期发病率和死亡率，限制了其在临床实践中[4，5]应用。在这里，我们调查了使用外部射频（RF），如手稿最近已经接受了在欧洲呼吸杂志出版单边emphysema.FootnotesThis大鼠模型的一种新型体外治疗肺气肿的可能性。据审稿，并通过我们的制作团队排版之前在这里其已接受的形式出版。经过这些生产工艺齐全，作者已经批准了造成证据，文章将在网上移动到ERJ最新一期。请打开或下载PDF浏览想看这个article.Conflict：和田博士感兴趣的study.Conflict进行期间报告从IKOMED补助金，补助金从MITACS，：颚博士MITACS（与iKomed联合申请资助的报告），感兴趣的study.Conflict进行期间：鹤田博士感兴趣的study.Conflict进行期间报告从IKOMED补助金，补助金从MITACS，：森谷博士在报告从IKOMED补助金，补助金从MITACS， conduct of the study.Conflict of interest: Dr. Tsutsui reports grants from IKOMED, grants from MITACS, during the conduct of the study.Conflict of interest: Dr. Tam has nothing to disclose.Conflict of interest: Dr. Vasilescu has nothing to disclose.Conflict of interest: Dr. CHEUNG reports grants from Ikomed, grants from Mitac, during the conduct of the study.Conflict of interest: Dr. Yamasaki reports grants from IKOMED, grants from MITACS, during the conduct of the study.Conflict of interest: Dr. Lichtenstein reports In addition, Dr. Lichtenstein has a patent Method for selectively heating tissue issued to Ikomed Technologies Inc and Founder and Investor in Ikomed Technologies Inc..Conflict of interest: Dr. Machan reports he is an Investor in Ikomed Technologies.Conflict of interest: Dr. Gelbart reports In addition, Dr. Gelbart has a patent 8444635 licensed to Ikomed.Conflict of interest: Dr. Man has nothing to disclose.Conflict of interest: Dr. Sin reports grants from IKOMED, during the conduct of the study; grants from Merck, personal fees from Sanofi-Aventis, personal fees from Regeneron, grants and personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Novartis, outside the submitted work. ER -